NCT00275093: Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function |
|
|
| Completed | 1 | 130 | US | temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Hepatic Complications, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | 03/08 | | | |
NCT00659568: Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma |
|
|
| Completed | 1 | 28 | Canada | metformin hydrochloride, temsirolimus | London Health Sciences Centre | Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | 02/10 | 08/10 | | |
NCT01902160: Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Completed | 1 | 3 | US | Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Recurrent Adult Hodgkin Lymphoma | 05/15 | | | |
